BioNTech, Trims

BioNTech Trims 2026 Revenue Range and Commits $205 Million to a Faster FDA Lane

Published on 11/17/2026 at 11:40 | Editorial boerse-global.de
BioNTech narrowed its 2026 revenue guidance to €1.7-1.9 billion after a profitable Q3, and agreed to pay $205 million for a priority review voucher.
BioNTech Trims 2026 Revenue Range and Commits $205 Million to a Faster FDA Lane Illustration mit AI erstellt.

BioNTech has narrowed its full-year 2026 revenue guidance to a range of €1.7 billion to €1.9 billion, the company said alongside quarterly results that showed a return to profit in the third quarter even as the nine-month tally remained deeply negative.

The Mainz-based biotech booked €1.29 billion in revenue for the third quarter of 2026 and an IFRS net profit of €184.5 million. Over the nine months to the end of September, however, the picture reverses: revenue of €1.51 billion came with an IFRS net loss of €1.17 billion. The guidance band represents management's expectation for the full year, not revenue already booked.

Separately, BioNTech has agreed to pay $205 million in cash for a Priority Review Voucher from Scholar Rock, a instrument that shortens the US Food and Drug Administration's review clock. The company intends to deploy it on a future marketing application for an asset from its late-stage oncology pipeline — a filing that has not yet been submitted, rather than an approval already in hand.

Should investors sell immediately? Or is it worth buying BioNTech?

A Deal Still Short of Closing

The voucher purchase remains subject to customary closing conditions, including clearance under the Hart-Scott-Rodino antitrust framework. BioNTech has framed both the transaction and the voucher's eventual use as agreed intentions: the payment is tied explicitly to a planned filing within that late-clinical oncology portfolio, and completion of the deal is a separate step from the agreement itself.

On the sell side, H.C. Wainwright's Robert Burns cut his price target on BioNTech to $110 from $130 on November 9, according to media reports, while leaving his buy rating on the shares intact. The lower target therefore reflected a recalibration of valuation rather than a change of heart on the stock.

Ahead of the open, the shares were down 0.5%. No link between that move and either the voucher agreement or the quarterly figures has been established.

Ad

BioNTech Stock: New Analysis - 17 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

Disclaimer...
en | US09075V1026 | BIONTECH | boerse | 70526117 |